Topic: Notes From the ASCO ,June 2012(current info may be sensitive to some)
Now and then I will post the information I learned here whenn I review my notes during those sessions. Here is one . BUT
IF YOU ARE NOT COMFORTABLE TO READ ABOUT IT ,THEN JUST SKIP IT.
I went thru the notes from the ASCO 2012 convention about CCA; One of the he author belief that " first, there is no definitive evidence we have ever benefited patients with adjuvant therapy for biliary tract cancers; Second, it is possible that adjuvant therapy will have differential effects depending on site of primary(IH,hilar,GB,EH) and third, the role of radiation may vary depending on site of primary." The author also indicated the challenges of treating biliary cancers because of " the heterogeneous of the disease. It is a uncommon tumor -----and CCA and HCC are lumped together in annual statistics( in the past).Multiple locations-- intrahepatic,extrahepatic(bile ducts,Klatzkin,periampullary); gallbadder. and we can't be sure that these locations are truly the same pathology; and there are mixed tumor types(cholangiocellular). He concluded that in systemic therapy for biliary cancers, chemotherapy is the standard treatment and the level1 evidence standard is gemcitabine and cisplatin. Other combined regimens have activity. The FUTURE of this disease should lie in targeted therapies and there are a lot of targets and these should be applied wisely,however ,these are rare tumors and subdividing them by biomarkers may prove difficult."